title: The effect of time to antifungal therapy on mortality in Candidemia associated septic shock.
abstract: The timely administration of appropriate antifungal therapy for Candida bloodstream infections (CBSI) improves clinical outcomes. However, little data exist on the effect of antifungal therapy in patients with septic shock and candidemia. We describe antifungal treatment of patients with septic shock due to CBSI and its impact on in-hospital mortality. We retrospectively reviewed medical records of hospitalized patients identified with at least one positive blood culture for Candida between January 2003 and June 2007. All septic shock patients received vasopressor therapy and had candidemia within 72 hours of refractory shock. Data collected included demographics, comorbidities, antibiotic exposure, in-hospital mortality, and intensive care-related factors. Acute Physiology and Chronic Health Evaluation II scores were calculated. Time to antifungal therapy was defined as the interval between time of collection of the first positive Candida blood culture and the time when appropriate antifungal therapy was initiated. Univariate and multivariate analyses were performed to identify variables associated with in-patient mortality. Classification and regression tree analysis was used to identify the mortality breakpoint between early and late antifungal therapy. Septic shock developed in 23% (31 of 135) patients with CBSI. In-hospital mortality was 68%. Nonalbicans Candida spp. accounted for 48% of blood isolates. Appropriate antifungal therapy was administered to 24 patients; 15 (63%) of these patients died. Classification and regression tree analysis revealed that patients who received appropriate antifungal therapy within 15 hours of collecting the first positive Candida blood culture had improved survival (P = 0.03). Early, appropriate antifungal therapy improves survival among patients with septic shock due to CBSI.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Rush University Medical Center, Chicago, IL 60612, USA. gourang_p_patel@rush.edu
authors.forename: Gourang P
authors.initials: GP
authors.lastname: Patel
authors.forename: David
authors.initials: D
authors.lastname: Simon
authors.forename: Marc
authors.initials: M
authors.lastname: Scheetz
authors.forename: Christopher W
authors.initials: CW
authors.lastname: Crank
authors.forename: Thomas
authors.initials: T
authors.lastname: Lodise
authors.forename: Nimish
authors.initials: N
authors.lastname: Patel
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy* / Q000401:mortality*; D004334:Drug Administration Schedule; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D012772:Shock, Septic / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality*; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000935:Antifungal Agents